Stocks and Investing
Stocks and Investing
Fri, March 1, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Silvan Tuerkcan Initiated (ACRV) at Buy and Held Target at $14 on, Mar 1st, 2024
Silvan Tuerkcan of JMP Securities, Initiated "Acrivon Therapeutics, Inc." (ACRV) at Buy and Held Target at $14 on, Mar 1st, 2024.
Silvan has made no other calls on ACRV in the last 4 months.
There is 1 other peer that has a rating on ACRV. Out of the 1 peers that are also analyzing ACRV, 0 agree with Silvan's Rating of Hold.
This is the rating of the analyst that currently disagrees with Silvan
- Etzer Darout of "BMO Capital" Maintained at Buy with Decreased Target to $24 on, Friday, November 10th, 2023
Contributing Sources